INNOCAN PHARMA Corp
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Iris Bincovich
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1015, 926 – 5 Avenue SW Calgary AB Canada T2P 0N7
- IPO Date
- Nov 27, 2020
- Website
- innocanpharma.com
- Similar Companies
- Business
- INNOCAN PHARMA Corp (Ticker: INNPF) is a clinical-stage biopharmaceutical company focused on developing innovative cannabinoid-based therapeutics for pain management, inflammation, and neurological disorders. The company offers a portfolio of proprietary products including NanoSRT oral capsules for systemic pain relief; ExosKTK topical gel utilizing exosome technology for localized pain and inflammation treatment; and Amolyt Pharma's peptide-based therapeutics targeting rare endocrine disorders, delivered through advanced nano-drug delivery platforms. These products leverage patented NanoSRT (nanoparticle self-emulsifying release technology) and exosome delivery systems to enhance bioavailability, stability, and targeted efficacy; the company also provides preclinical and clinical development services for cannabinoid formulations. INNOCAN operates primarily in Israel and the United States, with headquarters in Herzliya, Israel, founded in 2017 as a subsidiary of Canndoc Ltd., which was later acquired by Emmac Life Sciences in 2023. Recent major developments include the completion of a Phase 2 clinical trial for NanoSRT in 2024 demonstrating significant pain reduction in chronic pain patients; a strategic partnership with Mechano Therapeutics announced in early 2025 to co-develop exosome-based pain therapies; and a USD 10 million funding round closed in November 2025 led by institutional investors to support Phase 3 trials and U.S. market expansion. In late 2025, the company underwent a corporate reorganization following Emmac's integration, streamlining operations across its Israeli and U.S. subsidiaries to accelerate global commercialization efforts.
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries
Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)